{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:23:46Z","timestamp":1777047826397,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H<jats:sub>2<\/jats:sub>RAs) are used for gastro-esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs, H<jats:sub>2<\/jats:sub>RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full\/standard dose of esomeprazole at 40\u2009mg per day was the most efficient in healing among nine different dosages of PPIs and H<jats:sub>2<\/jats:sub>RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)\/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses. This research suggests that the full\/standard doses (40\u2009mg per day) of esomeprazole should be recommended as first-line treatments for GERD in adults for short-term therapy.<\/jats:p>","DOI":"10.1038\/srep41021","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T13:29:30Z","timestamp":1484832570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Meta-Analysis and GRADE system"],"prefix":"10.1038","volume":"7","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joey S. W.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Xia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gong-Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Zhu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Tao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"BFsrep41021_CR1","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","volume":"100","author":"KR DeVault","year":"2005","unstructured":"DeVault, K. R. et al. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 100, 190\u2013200, doi: 10.1111\/j.1572-0241.2005.41217.x (2005).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep41021_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1136\/gutjnl-2012-304269","volume":"63","author":"HB El-Serag","year":"2014","unstructured":"El-Serag, H. B. et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 63, 871\u2013880, doi: 10.1136\/gutjnl-2012-304269 (2014).","journal-title":"Gut"},{"key":"BFsrep41021_CR3","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1111\/j.1572-0241.2000.02235.x","volume":"95","author":"MA Eloubeidi","year":"2000","unstructured":"Eloubeidi, M. A. et al. Health-related quality of life and severity of symptoms in patients with Barrett\u2019s esophagus and gastroesophageal reflux disease patients without Barrett\u2019s esophagus. Am J Gastroenterol. 95, 1881\u20131887, doi: 10.1111\/j.1572-0241.2000.02235.x (2000).","journal-title":"Am J Gastroenterol"},{"key":"BFsrep41021_CR4","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4321\/S1130-01082014000200006","volume":"106","author":"I Waxman","year":"2014","unstructured":"Waxman, I. et al. Endoscopic diagnosis and therapies for Barrett esophagus. A review. Rev Esp Enferm Dig. 106, 103\u2013119 (2014).","journal-title":"Rev Esp Enferm Dig"},{"key":"BFsrep41021_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/dote.12228","volume":"28","author":"A Menezes","year":"2015","unstructured":"Menezes, A. et al. Adherence to the 2011 American Gastroenterological Association medical position statement for the diagnosis and management of Barrett\u2019s esophagus. Diseases of the Esophagus. 28, 538\u2013546, doi: 10.1111\/dote.12228 (2015).","journal-title":"Diseases of the Esophagus."},{"key":"BFsrep41021_CR6","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1056\/NEJMcp0804684","volume":"359","author":"PJ Kahrilas","year":"2008","unstructured":"Kahrilas, P. J. Clinical practice. Gastroesophageal reflux disease. N Engl J Med. 359, 1700\u20131707, doi: 10.1056\/NEJMcp0804684 (2008).","journal-title":"N Engl J Med"},{"key":"BFsrep41021_CR7","doi-asserted-by":"crossref","unstructured":"Harnik, I. G. Gastroesophageal Reflux Disease. Annals of Internal Medicine. 163, ITC1, doi: 10.7326\/aitc201507070 (2015).","DOI":"10.7326\/AITC201507070"},{"key":"BFsrep41021_CR8","unstructured":"Internal Clinical Guidelines T. Dyspepsia and gastro-oesophageal reflux disease: investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or both. Clinical guideline (update) (2014)."},{"key":"BFsrep41021_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ajg.2012.444","volume":"108","author":"PO Katz","year":"2013","unstructured":"Katz, P. O. et al. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 108, 308\u2013328; quiz 329, doi: 10.1038\/ajg.2012.444 (2013).","journal-title":"Am J Gastroenterol."},{"key":"BFsrep41021_CR10","doi-asserted-by":"publisher","first-page":"f1908","DOI":"10.1136\/bmj.f1908","volume":"346","author":"AM Grant","year":"2013","unstructured":"Grant, A. M. et al. Minimal access surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLUX). BMJ. 346, f1908, doi: 10.1136\/bmj.f1908 (2013).","journal-title":"BMJ"},{"key":"BFsrep41021_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/ajg.2013.71","volume":"108","author":"ES Dellon","year":"2013","unstructured":"Dellon, E. S. et al. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 108, 679\u2013692; quiz 693, doi: 10.1038\/ajg.2013.71 (2013).","journal-title":"Am J Gastroenterol."},{"key":"BFsrep41021_CR12","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1053\/j.gastro.2008.08.045","volume":"135","author":"PJ Kahrilas","year":"2008","unstructured":"Kahrilas, P. J. et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 135, 1383\u20131391, 1391, e1381\u20131385, doi: 10.1053\/j.gastro.2008.08.045 (2008).","journal-title":"Gastroenterology"},{"key":"BFsrep41021_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.tips.2011.02.007","volume":"32","author":"T Hershcovici","year":"2011","unstructured":"Hershcovici, T. et al. Pharmacological management of GERD: where does it stand now? Trends Pharmacol Sci. 32, 258\u2013264, doi: 10.1016\/j.tips.2011.02.007 (2011).","journal-title":"Trends Pharmacol Sci"},{"key":"BFsrep41021_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1365-2036.2010.04516.x","volume":"33","author":"L Laine","year":"2011","unstructured":"Laine, L. et al. Randomised clinical trial: a novel rabeprazole extended release 50\u2009mg formulation vs. esomeprazole 40\u2009mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Aliment Pharmacol Ther. 33, 203\u2013212, doi: 10.1111\/j.1365-2036.2010.04516.x (2011).","journal-title":"Aliment Pharmacol Ther"},{"key":"BFsrep41021_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00535-010-0283-8","volume":"45","author":"S Ohara","year":"2010","unstructured":"Ohara, S. et al. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol. 45, 1219\u20131227, doi: 10.1007\/s00535-010-0283-8 (2010).","journal-title":"J Gastroenterol."},{"key":"BFsrep41021_CR16","doi-asserted-by":"publisher","first-page":"4467","DOI":"10.3748\/wjg.v13.i33.4467","volume":"13","author":"A Pilotto","year":"2007","unstructured":"Pilotto, A. et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 13, 4467\u20134472 (2007).","journal-title":"World J Gastroenterol"},{"key":"BFsrep41021_CR17","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.3748\/wjg.v18.i19.2390","volume":"18","author":"AA Kobeissy","year":"2012","unstructured":"Kobeissy, A. A. et al. A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease. World J Gastroenterol. 18, 2390\u20132395, doi: 10.3748\/wjg.v18.i19.2390 (2012).","journal-title":"World J Gastroenterol"},{"key":"BFsrep41021_CR18","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s10620-012-2297-y","volume":"57","author":"YK Cho","year":"2012","unstructured":"Cho, Y. K. et al. Efficacy of pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial. Dig Dis Sci. 57, 3189\u20133194, doi: 10.1007\/s10620-012-2297-y (2012).","journal-title":"Dig Dis Sci"},{"key":"BFsrep41021_CR19","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00535-011-0402-1","volume":"46","author":"VP Tan","year":"2011","unstructured":"Tan, V. P. et al. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. J Gastroenterol. 46, 906\u2013912, doi: 10.1007\/s00535-011-0402-1 (2011).","journal-title":"J Gastroenterol."},{"key":"BFsrep41021_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2036.2010.04519.x","volume":"33","author":"AH Dabholkar","year":"2011","unstructured":"Dabholkar, A. H. et al. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 33, 366\u2013377, doi: 10.1111\/j.1365-2036.2010.04519.x (2011).","journal-title":"Aliment Pharmacol Ther"},{"key":"BFsrep41021_CR21","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/j.1365-2036.2009.04064.x","volume":"30","author":"DA Peura","year":"2009","unstructured":"Peura, D. A. et al. Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther. 30, 459\u2013468, doi: 10.1111\/j.1365-2036.2009.04064.x (2009).","journal-title":"Aliment Pharmacol Ther"},{"key":"BFsrep41021_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4236\/pp.2013.42028","volume":"4","author":"R Bola\u00f1os-D\u00edaz","year":"2013","unstructured":"Bola\u00f1os-D\u00edaz, R. et al. Efficacy of Drugs Used in Gastro-Oesophageal Reflux: Network Meta-Analysis. Pharmacology & Pharmacy. 4, 201\u2013208 (2013).","journal-title":"Pharmacology & Pharmacy"},{"key":"BFsrep41021_CR23","doi-asserted-by":"publisher","first-page":"327571","DOI":"10.1155\/2013\/327571","volume":"2013","author":"XM Xia","year":"2013","unstructured":"Xia, X. M. et al. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20\u2009mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013, 327571, doi: 10.1155\/2013\/327571 (2013).","journal-title":"Gastroenterol Res Pract"},{"key":"BFsrep41021_CR24","doi-asserted-by":"publisher","first-page":"CD002095","DOI":"10.1002\/14651858.CD002095.pub5","volume":"5","author":"KE Sigterman","year":"2013","unstructured":"Sigterman, K. E. et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 5, CD002095, doi: 10.1002\/14651858.CD002095.pub5 (2013).","journal-title":"Cochrane Database Syst Rev"},{"key":"BFsrep41021_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1161\/circoutcomes.114.000825","volume":"7","author":"H Naci","year":"2014","unstructured":"Naci, H. et al. Evidence-Based Prescribing: Combining Network Meta-Analysis With Multicriteria Decision Analysis to Choose Among Multiple Drugs. Circulation: Cardiovascular Quality and Outcomes. 7, 787\u2013792, doi: 10.1161\/circoutcomes.114.000825 (2014).","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"BFsrep41021_CR26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1345\/aph.1M685","volume":"44","author":"C Abel","year":"2010","unstructured":"Abel, C. et al. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann Pharmacother. 44, 871\u2013877, doi: 10.1345\/aph.1M685 (2010).","journal-title":"Ann Pharmacother."},{"key":"BFsrep41021_CR27","doi-asserted-by":"publisher","first-page":"MR000033","DOI":"10.1002\/14651858.MR000033.pub2","volume":"12","author":"A Lundh","year":"2012","unstructured":"Lundh, A. et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 12, MR000033, doi: 10.1002\/14651858.MR000033.pub2 (2012).","journal-title":"Cochrane Database Syst Rev"},{"key":"BFsrep41021_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.10.001","volume":"62","author":"G Salanti","year":"2009","unstructured":"Salanti, G. et al. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol. 62, 857\u2013864, doi: 10.1016\/j.jclinepi.2008.10.001 (2009).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR29","unstructured":"Higgins, J. et al. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011, Available from www.cochrane-handbook.org. Accessed Oct 1, 2011."},{"key":"BFsrep41021_CR30","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2146\/ajhp070369","volume":"65","author":"T Gerhard","year":"2008","unstructured":"Gerhard, T. Bias: considerations for research practice. Am J Health Syst Pharm. 65, 2159\u20132168, doi: 10.2146\/ajhp070369 (2008).","journal-title":"Am J Health Syst Pharm"},{"key":"BFsrep41021_CR31","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.jclinepi.2010.01.005","volume":"63","author":"S Dias","year":"2010","unstructured":"Dias, S. et al. Study designs to detect sponsorship and other biases in systematic reviews. J Clin Epidemiol. 63, 587\u2013588, doi: 10.1016\/j.jclinepi.2010.01.005 (2010).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/sim.6372","volume":"34","author":"H-P Piepho","year":"2015","unstructured":"Piepho, H.-P. et al. Multiplicative interaction in network meta-analysis. Statistics in Medicine. 34, 582\u2013594, doi: 10.1002\/sim.6372 (2015).","journal-title":"Statistics in Medicine"},{"key":"BFsrep41021_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jclinepi.2014.12.016","volume":"68","author":"ME Flacco","year":"2015","unstructured":"Flacco, M. E. et al. Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor. Journal of Clinical Epidemiology. 68, 811\u2013820, doi: 10.1016\/j.jclinepi.2014.12.016 (2015).","journal-title":"Journal of Clinical Epidemiology"},{"key":"BFsrep41021_CR34","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.jval.2011.05.042","volume":"14","author":"J Madan","year":"2011","unstructured":"Madan, J. et al. Consistency between direct and indirect trial evidence: is direct evidence always more reliable? Value Health. 14, 953\u2013960, doi: 10.1016\/j.jval.2011.05.042 (2011).","journal-title":"Value Health."},{"key":"BFsrep41021_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","volume":"3","author":"JP Higgins","year":"2012","unstructured":"Higgins, J. P. et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 3, 98\u2013110, doi: 10.1002\/jrsm.1044 (2012).","journal-title":"Res Synth Methods"},{"key":"BFsrep41021_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jclinepi.2012.06.022","volume":"66","author":"T Xiong","year":"2013","unstructured":"Xiong, T. et al. Overall similarity and consistency assessment scores are not sufficiently accurate for predicting discrepancy between direct and indirect comparison estimates. J Clin Epidemiol. 66, 184\u2013191, doi: 10.1016\/j.jclinepi.2012.06.022 (2013).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR37","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989x12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias, S. et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making. 33, 641\u2013656, doi: 10.1177\/0272989x12455847 (2013).","journal-title":"Med Decis Making"},{"key":"BFsrep41021_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jval.2014.01.004","volume":"17","author":"JP Jansen","year":"2014","unstructured":"Jansen, J. P. et al. Indirect treatment comparison\/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 17, 157\u2013173, doi: 10.1016\/j.jval.2014.01.004 (2014).","journal-title":"Value Health."},{"key":"BFsrep41021_CR39","doi-asserted-by":"publisher","first-page":"g5630","DOI":"10.1136\/bmj.g5630","volume":"349","author":"MA Puhan","year":"2014","unstructured":"Puhan, M. A. et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. Bmj. 349, g5630\u2013g5630, doi: 10.1136\/bmj.g5630 (2014).","journal-title":"Bmj"},{"key":"BFsrep41021_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","volume":"24","author":"AE Ades","year":"2006","unstructured":"Ades, A. E. et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics. 24, 1\u201319 (2006).","journal-title":"Pharmacoeconomics"},{"key":"BFsrep41021_CR41","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1177\/0272989x13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias, S. et al. Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making. 33, 618\u2013640, doi: 10.1177\/0272989x13485157 (2013).","journal-title":"Med Decis Making"},{"key":"BFsrep41021_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/eb-2014-101900","volume":"17","author":"D Mavridis","year":"2014","unstructured":"Mavridis, D. et al. Addressing missing outcome data in meta-analysis. Evid Based Ment Health. 17, 85\u201389, doi: 10.1136\/eb-2014-101900 (2014).","journal-title":"Evid Based Ment Health"},{"key":"BFsrep41021_CR43","doi-asserted-by":"publisher","first-page":"h2445","DOI":"10.1136\/bmj.h2445","volume":"350","author":"I Abraha","year":"2015","unstructured":"Abraha, I. et al. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. Bmj. 350, h2445\u2013h2445, doi: 10.1136\/bmj.h2445 (2015).","journal-title":"Bmj"},{"key":"BFsrep41021_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/jrsm.57","volume":"3","author":"A Chaimani","year":"2012","unstructured":"Chaimani, A. et al. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. Res Synthesis Methods. 3, 161\u2013176 (2012).","journal-title":"Res Synthesis Methods"},{"key":"BFsrep41021_CR45","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1046\/j.1525-1497.2003.20833.x","volume":"18","author":"B van Pinxteren","year":"2003","unstructured":"van Pinxteren, B. et al. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med. 18, 755\u2013763 (2003).","journal-title":"J Gen Intern Med"},{"key":"BFsrep41021_CR46","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu, G. et al. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 23, 3105\u20133124, doi: 10.1002\/sim.1875 (2004).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR47","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","volume":"7","author":"S Brooks","year":"1998","unstructured":"Brooks, S. et al. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat. 7, 434\u2013445 (1998).","journal-title":"J Comput Graph Stat"},{"key":"BFsrep41021_CR48","doi-asserted-by":"crossref","unstructured":"Greco, T. et al. A Bayesian network meta-analysis for binary outcome: how to do it. Stat Methods Med Res, doi: 10.1177\/0962280213500185 (2013).","DOI":"10.1177\/0962280213500185"},{"key":"BFsrep41021_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti, G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 3, 80\u201397 (2012).","journal-title":"Res Synth Methods"},{"key":"BFsrep41021_CR50","doi-asserted-by":"publisher","first-page":"d4909","DOI":"10.1136\/bmj.d4909","volume":"343","author":"F Song","year":"2011","unstructured":"Song, F. et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ. 343, d4909, doi: 10.1136\/bmj.d4909 (2011).","journal-title":"BMJ"},{"key":"BFsrep41021_CR51","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","volume":"29","author":"S Dias","year":"2010","unstructured":"Dias, S. et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 29, 932\u2013944, doi: 10.1002\/sim.3767 (2010).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR52","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1002\/sim.6188","volume":"33","author":"D Jackson","year":"2014","unstructured":"Jackson, D. et al. A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med. 33, 3639\u20133654, doi: 10.1002\/sim.6188 (2014).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR53","doi-asserted-by":"publisher","first-page":"e35219","DOI":"10.1371\/journal.pone.0035219","volume":"7","author":"L Trinquart","year":"2012","unstructured":"Trinquart, L. et al. Impact of reporting bias in network meta-analysis of antidepressant placebo-controlled trials. PLoS One. 7, e35219, doi: 10.1371\/journal.pone.0035219 (2012).","journal-title":"PLoS One."},{"key":"BFsrep41021_CR54","doi-asserted-by":"publisher","first-page":"e20679","DOI":"10.1371\/journal.pone.0020679","volume":"6","author":"YH Koog","year":"2011","unstructured":"Koog, Y. H. et al. Three-armed trials including placebo and no-treatment groups may be subject to publication bias: systematic review. PLoS One. 6, e20679, doi: 10.1371\/journal.pone.0020679 (2011).","journal-title":"PLoS One."},{"key":"BFsrep41021_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/sim.3869","volume":"29","author":"L Govan","year":"2010","unstructured":"Govan, L. et al. Controlling ecological bias in evidence synthesis of trials reporting on collapsed and overlapping covariate categories. Stat Med. 29, 1340\u20131356, doi: 10.1002\/sim.3869 (2010).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR56","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2288-12-150","volume":"12","author":"L Trinquart","year":"2012","unstructured":"Trinquart, L. et al. Adjustment for reporting bias in network meta-analysis of antidepressant trials. BMC Med Res Methodol. 12, 150, doi: 10.1186\/1471-2288-12-150 (2012).","journal-title":"BMC Med Res Methodol"},{"key":"BFsrep41021_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1467-9868.02022","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter, D. J. et al. Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society: Series B. 64, 1\u201334 (2002).","journal-title":"Journal of the Royal Statistical Society: Series B"},{"key":"BFsrep41021_CR58","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0272989x13485155","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias, S. et al. Evidence synthesis for decision making 5: the baseline natural history model. Med Decis Making. 33, 657\u2013670, doi: 10.1177\/0272989x13485155 (2013).","journal-title":"Med Decis Making"},{"key":"BFsrep41021_CR59","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jval.2014.10.006","volume":"18","author":"RK Owen","year":"2015","unstructured":"Owen, R. K. et al. Network Meta-Analysis: Development of a Three-Level Hierarchical Modeling Approach Incorporating Dose-Related Constraints. Value in Health. 18, 116\u2013126, doi: 10.1016\/j.jval.2014.10.006 (2015).","journal-title":"Value in Health"},{"key":"BFsrep41021_CR60","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/sim.3594","volume":"28","author":"NJ Cooper","year":"2009","unstructured":"Cooper, N. J. et al. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 28, 1861\u20131881, doi: 10.1002\/sim.3594 (2009).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR61","doi-asserted-by":"publisher","first-page":"254","DOI":"10.7326\/0003-4819-136-3-200202050-00022","volume":"136","author":"KF Schulz","year":"2002","unstructured":"Schulz, K. F. et al. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 136, 254\u2013259 (2002).","journal-title":"Ann Intern Med"},{"key":"BFsrep41021_CR62","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/sim.1761","volume":"23","author":"MJ Sweeting","year":"2004","unstructured":"Sweeting, M. J. et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 23, 1351\u20131375, doi: 10.1002\/sim.1761 (2004).","journal-title":"Stat Med."},{"key":"BFsrep41021_CR63","unstructured":"Wu., T. et al. Investigation of authenticity of \u2018claimed\u2019 randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. XIV Cochrane Colloquium; Dublin, 23\u201326 (2006)."},{"key":"BFsrep41021_CR64","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","volume":"64","author":"G Salanti","year":"2011","unstructured":"Salanti, G. et al. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 64, 163\u2013171, doi: 10.1016\/j.jclinepi.2010.03.016 (2011).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR65","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jclinepi.2012.01.012","volume":"66","author":"GH Guyatt","year":"2013","unstructured":"Guyatt, G. H. et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 66, 158\u2013172, doi: 10.1016\/j.jclinepi.2012.01.012 (2013).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR66","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jclinepi.2012.03.013","volume":"66","author":"J Andrews","year":"2013","unstructured":"Andrews, J. et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 66, 719\u2013725, doi: 10.1016\/j.jclinepi.2012.03.013 (2013).","journal-title":"J Clin Epidemiol"},{"key":"BFsrep41021_CR67","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/m14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton, B. et al. The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Annals of Internal Medicine. 162, 777, doi: 10.7326\/m14-2385 (2015).","journal-title":"Annals of Internal Medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep41021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41021","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep41021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T22:25:37Z","timestamp":1719008737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep41021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,19]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,2,20]]}},"alternative-id":["BFsrep41021"],"URL":"https:\/\/doi.org\/10.1038\/srep41021","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,19]]},"assertion":[{"value":"26 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41021"}}